10-K Filing

Astrana Health, Inc. CIK: 1083446 FY 2018

Filing Information

Form Type	10-K
Accession Number	`0001144204-19-014671`
Period End Date	20181231
Filing Date	20190318
Fiscal Year	2018
Fiscal Period	FY
XBRL Instance	ameh-20181231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 95 Income Statement 50 Cash Flow Statement 125 Stockholders Equity 30

Balance Sheet 95 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$106.89M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$99.75M	USD	Point-in-time
Restricted cash	`RestrictedCashCurrent`	-	USD	Point-in-time
Restricted cash	`RestrictedCashCurrent`	$18.01M	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Investment in marketable securities	`MarketableSecuritiesCurrent`	$1.13M	USD	Point-in-time
Investment in marketable securities	`MarketableSecuritiesCurrent`	$1.14M	USD	Point-in-time
Receivables, net	`AccountsReceivableNetCurrent`	$7.73M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Receivables, net	`AccountsReceivableNetCurrent`	$7.60M	USD	Point-in-time
Receivables, net related parties	`DueFromRelatedPartiesCurrent`	$12.51M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	32.30M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	34.58M	shares	Point-in-time
Receivables, net related parties	`DueFromRelatedPartiesCurrent`	$48.72M	USD	Point-in-time
Treasury Stock, Common, Shares	`TreasuryStockCommonShares`	1.85M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$8.39M	USD	Point-in-time
Treasury Stock, Common, Shares	`TreasuryStockCommonShares`	1.68M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$5.14M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$144.16M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$172.86M	USD	Point-in-time
Land, property and equipment, net	`PropertyPlantAndEquipmentNet`	$12.72M	USD	Point-in-time
Land, property and equipment, net	`PropertyPlantAndEquipmentNet`	$13.81M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$103.53M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$86.88M	USD	Point-in-time
Goodwill	`Goodwill`	$103.41M	USD	Point-in-time
Goodwill	`Goodwill`	$185.81M	USD	Point-in-time
Goodwill	`Goodwill`	$189.85M	USD	Point-in-time
Loans receivable related parties	`DueFromRelatedPartiesNoncurrent`	$15.00M	USD	Point-in-time
Loans receivable related parties	`DueFromRelatedPartiesNoncurrent`	$17.50M	USD	Point-in-time
Investments in other entities equity method	`EquityMethodInvestments`	$34.88M	USD	Point-in-time
Investments in other entities equity method	`EquityMethodInvestments`	$21.90M	USD	Point-in-time
Investment in a privately held entity that does not report net asset value per share	`InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValuePerShare`	-	USD	Point-in-time
Investment in a privately held entity that does not report net asset value per share	`InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValuePerShare`	$405.00K	USD	Point-in-time
Restricted cash long-term	`RestrictedCashNoncurrent`	$745.47K	USD	Point-in-time
Restricted cash long-term	`RestrictedCashNoncurrent`	$745.24K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.63M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.21M	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$346.48M	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$340.14M	USD	Point-in-time
Total assets	`Assets`	$490.64M	USD	Point-in-time
Total assets	`Assets`	$513.00M	USD	Point-in-time
Lines of credit related party	`DueToRelatedPartiesCurrent`	-	USD	Point-in-time
Lines of credit related party	`DueToRelatedPartiesCurrent`	$5.03M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$13.28M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$25.08M	USD	Point-in-time
Provider incentives payable	`IncentivePayableCurrent`	-	USD	Point-in-time
Provider incentives payable	`IncentivePayableCurrent`	$21.50M	USD	Point-in-time
Fiduciary accounts payable	`FiduciaryAccountsPayableCurrent`	$2.02M	USD	Point-in-time
Fiduciary accounts payable	`FiduciaryAccountsPayableCurrent`	$1.54M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$63.97M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$18.96M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$33.64M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$11.62M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$3.20M	USD	Point-in-time
Bank loan, short-term	`ShortTermBankLoansAndNotesPayable`	$40.26K	USD	Point-in-time
Bank loan, short-term	`ShortTermBankLoansAndNotesPayable`	$510.39K	USD	Point-in-time
Capital lease obligations	`CapitalLeaseObligationsCurrent`	$101.74K	USD	Point-in-time
Capital lease obligations	`CapitalLeaseObligationsCurrent`	$98.74K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$72.02M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$109.60M	USD	Point-in-time
Lines of credit - related party	`DueToRelatedPartiesNoncurrent`	-	USD	Point-in-time
Lines of credit - related party	`DueToRelatedPartiesNoncurrent`	$13.00M	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$19.62M	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$24.92M	USD	Point-in-time
Liability for unissued equity shares	`LiabilityForUnissuedEquitySharesNoncurrent`	$1.19M	USD	Point-in-time
Liability for unissued equity shares	`LiabilityForUnissuedEquitySharesNoncurrent`	$1.19M	USD	Point-in-time
Dividend payable	`DividendPayableNoncurrent`	-	USD	Point-in-time
Dividend payable	`DividendPayableNoncurrent`	$18.00M	USD	Point-in-time
Capital lease obligations, net of current portion	`CapitalLeaseObligationsNoncurrent`	$517.26K	USD	Point-in-time
Capital lease obligations, net of current portion	`CapitalLeaseObligationsNoncurrent`	$619.00K	USD	Point-in-time
Total noncurrent liabilities	`LiabilitiesNoncurrent`	$34.32M	USD	Point-in-time
Total noncurrent liabilities	`LiabilitiesNoncurrent`	$44.72M	USD	Point-in-time
Total liabilities	`Liabilities`	$154.32M	USD	Point-in-time
Total liabilities	`Liabilities`	$106.34M	USD	Point-in-time
Commitments and Contingencies (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Noncontrolling interest in Allied Pacific of California IPA	`TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests`	$225.12M	USD	Point-in-time
Noncontrolling interest in Allied Pacific of California IPA	`TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests`	$172.13M	USD	Point-in-time
Common stock, par value $0.001; 100,000,000 shares authorized, 34,578,040 and 32,304,876 shares outstanding, excluding 1,850,603 and 1,682,110 Treasury shares, at December 31, 2018 and 2017, respectively	`CommonStockValue`	$32.30K	USD	Point-in-time
Common stock, par value $0.001; 100,000,000 shares authorized, 34,578,040 and 32,304,876 shares outstanding, excluding 1,850,603 and 1,682,110 Treasury shares, at December 31, 2018 and 2017, respectively	`CommonStockValue`	$34.58K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$158.18M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$162.72M	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$17.79M	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.73M	USD	Point-in-time
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$180.55M	USD	Point-in-time
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$159.95M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$998.32K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$4.24M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$164.18M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$181.54M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$87.59M	USD	Point-in-time
Total liabilities, mezzanine equity and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$490.64M	USD	Point-in-time
Total liabilities, mezzanine equity and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$513.00M	USD	Point-in-time

Income Statement 50 line items

Line Item	Tag	Value	Unit	Period
Total revenue	`Revenues`	$519.91M	USD	Annual
Total revenue	`Revenues`	$356.36M	USD	Annual
Cost of services	`CostOfGoodsAndServicesSold`	$361.13M	USD	Annual
Cost of services	`CostOfGoodsAndServicesSold`	$273.45M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$43.35M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$26.25M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$19.08M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$19.30M	USD	Annual
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	-	USD	Annual
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	$3.89M	USD	Annual
Impairment of goodwill and intangibles	`GoodwillAndIntangibleAssetImpairment`	$2.43M	USD	Annual
Impairment of goodwill and intangibles	`GoodwillAndIntangibleAssetImpairment`	$3.80M	USD	Annual
Total expenses	`OperatingExpenses`	$321.21M	USD	Annual
Total expenses	`OperatingExpenses`	$431.48M	USD	Annual
Income from operations	`OperatingIncomeLoss`	$88.43M	USD	Annual
Income from operations	`OperatingIncomeLoss`	$35.15M	USD	Annual
Loss from equity method investments	`IncomeLossFromEquityMethodInvestments`	$-8.13M	USD	Annual
Loss from equity method investments	`IncomeLossFromEquityMethodInvestments`	$-1.11M	USD	Annual
Interest expense	`InterestExpense`	$79.69K	USD	Annual
Interest expense	`InterestExpense`	$560.51K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$1.26M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$1.02M	USD	Annual
Change in fair value of derivative instrument	`GainLossOnDerivativeInstrumentsNetPretax`	$-44.89K	USD	Annual
Change in fair value of derivative instrument	`GainLossOnDerivativeInstrumentsNetPretax`	-	USD	Annual
Gain on settlement of preexisting note receivable from ApolloMed	`GainLossOnSaleOfNotesReceivable`	-	USD	Annual
Gain on settlement of preexisting note receivable from ApolloMed	`GainLossOnSaleOfNotesReceivable`	$921.94K	USD	Annual
Gain from investments fair value adjustments	`GainLossOnInvestments`	-	USD	Annual
Gain from investments fair value adjustments	`GainLossOnInvestments`	$13.70M	USD	Annual
Other income	`OtherNonoperatingIncomeExpense`	$168.10K	USD	Annual
Other income	`OtherNonoperatingIncomeExpense`	$1.62M	USD	Annual
Total other (expense) income, net	`NonoperatingIncomeExpense`	$14.57M	USD	Annual
Total other (expense) income, net	`NonoperatingIncomeExpense`	$-5.81M	USD	Annual
Income before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$82.63M	USD	Annual
Income before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$49.71M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$22.36M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$3.89M	USD	Annual
Net income	`ProfitLoss`	$60.27M	USD	Annual
Net income	`ProfitLoss`	$45.82M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$49.43M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$20.02M	USD	Annual
Net income attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$10.84M	USD	Annual
Net income attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$25.80M	USD	Annual
Earnings per share basic	`EarningsPerShareBasic`	$0.33	USD	Annual
Earnings per share basic	`EarningsPerShareBasic`	$1.01	USD	Annual
Earnings per share diluted	`EarningsPerShareDiluted`	$0.29	USD	Annual
Earnings per share diluted	`EarningsPerShareDiluted`	$0.90	USD	Annual
Weighted average shares of common stock outstanding basic	`WeightedAverageNumberOfSharesOutstandingBasic`	25.53M	shares	Annual
Weighted average shares of common stock outstanding basic	`WeightedAverageNumberOfSharesOutstandingBasic`	32.89M	shares	Annual
Weighted average shares of common stock outstanding diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	28.66M	shares	Annual
Weighted average shares of common stock outstanding diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	37.91M	shares	Annual

Cash Flow Statement 125 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$60.27M	USD	Annual
Net income	`ProfitLoss`	$45.82M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$19.08M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$19.30M	USD	Annual
Loss of disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-41.78K	USD	Annual
Loss of disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	Annual
Impairment of goodwill and intangible assets	`GoodwillAndIntangibleAssetImpairment`	$2.43M	USD	Annual
Impairment of goodwill and intangible assets	`GoodwillAndIntangibleAssetImpairment`	$3.80M	USD	Annual
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	-	USD	Annual
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	$3.89M	USD	Annual
Share-based compensation	`AllocatedShareBasedCompensationExpense`	$2.74M	USD	Annual
Share-based compensation	`AllocatedShareBasedCompensationExpense`	$1.44M	USD	Annual
Unrealized loss (gain) from investment in equity securities	`UnrealizedGainLossOnInvestments`	$-25.00K	USD	Annual
Unrealized loss (gain) from investment in equity securities	`UnrealizedGainLossOnInvestments`	$86.00K	USD	Annual
Gain on settlement of preexisting note receivable from ApolloMed	`GainLossOnSaleOfNotesReceivable`	-	USD	Annual
Gain on settlement of preexisting note receivable from ApolloMed	`GainLossOnSaleOfNotesReceivable`	$921.94K	USD	Annual
Gain from investments fair value adjustments	`GainLossOnInvestments`	-	USD	Annual
Gain from investments fair value adjustments	`GainLossOnInvestments`	$13.70M	USD	Annual
Change in fair value of derivative instrument	`GainLossOnDerivativeInstrumentsNetPretax`	$-44.89K	USD	Annual
Change in fair value of derivative instrument	`GainLossOnDerivativeInstrumentsNetPretax`	-	USD	Annual
Loss from equity method investments	`IncomeLossFromEquityMethodInvestments`	$-8.13M	USD	Annual
Loss from equity method investments	`IncomeLossFromEquityMethodInvestments`	$-1.11M	USD	Annual
Deferred tax	`DeferredIncomeTaxExpenseBenefit`	$-20.68M	USD	Annual
Deferred tax	`DeferredIncomeTaxExpenseBenefit`	$-8.35M	USD	Annual
Receivable, net	`IncreaseDecreaseInAccountsReceivable`	$263.19K	USD	Annual
Receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-4.11M	USD	Annual
Receivable, net related parties	`IncreaseDecreaseInDueFromRelatedParties`	$-6.59M	USD	Annual
Receivable, net related parties	`IncreaseDecreaseInDueFromRelatedParties`	$28.36M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$-1.26M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$2.81M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-2.45K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$220.93K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-22.67M	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-3.69M	USD	Annual
Capitation incentives payable	`IncreasedecreaseInCapitationIncentivesPayable`	$-21.50M	USD	Annual
Capitation incentives payable	`IncreasedecreaseInCapitationIncentivesPayable`	$1.88M	USD	Annual
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$5.66M	USD	Annual
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$4.13M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$8.42M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$388.14K	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$51.83M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$25.50M	USD	Annual
Cash acquired in the Merger	`CashAcquiredFromAcquisition`	-	USD	Annual
Cash acquired in the Merger	`CashAcquiredFromAcquisition`	$37.11M	USD	Annual
Cash received from consolidation of VIE	`PaymentsForProceedsFromBusinessesAndInterestInAffiliates`	-	USD	Annual
Cash received from consolidation of VIE	`PaymentsForProceedsFromBusinessesAndInterestInAffiliates`	$-228.29K	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$5.28K	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$9.01K	USD	Annual
Proceeds from loans receivable	`ProceedsFromSaleOfLoansReceivable`	-	USD	Annual
Proceeds from loans receivable	`ProceedsFromSaleOfLoansReceivable`	$200.00K	USD	Annual
Advances to related parties loans receivable	`PaymentsToFundLongtermLoansToRelatedParties`	$10.00M	USD	Annual
Advances to related parties loans receivable	`PaymentsToFundLongtermLoansToRelatedParties`	$7.50M	USD	Annual
Dividends received from equity method investments	`ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital`	$607.41K	USD	Annual
Dividends received from equity method investments	`ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital`	$1.24M	USD	Annual
Proceeds on sale of investments in a privately held entity that does not report net asset value per share	`ProceedsOnSaleOfInvestmentPrivatelyHeldEntityThatDoesNotReportNAVPershare`	-	USD	Annual
Proceeds on sale of investments in a privately held entity that does not report net asset value per share	`ProceedsOnSaleOfInvestmentPrivatelyHeldEntityThatDoesNotReportNAVPershare`	$25.00K	USD	Annual
Purchases of investments in a privately held entity that does not report net asset value per share	`PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare`	-	USD	Annual
Purchases of investments in a privately held entity that does not report net asset value per share	`PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare`	$405.00K	USD	Annual
Purchases of investments equity method	`PaymentsToAcquireEquityMethodInvestments`	-	USD	Annual
Purchases of investments equity method	`PaymentsToAcquireEquityMethodInvestments`	$16.71M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.08M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.17M	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$26.72M	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-25.18M	USD	Annual
Dividends paid	`PaymentsOfDividends`	$17.76M	USD	Annual
Dividends paid	`PaymentsOfDividends`	$10.45M	USD	Annual
Change in noncontrolling interest capital	`ProceedsFromPaymentsToMinorityShareholders`	-	USD	Annual
Change in noncontrolling interest capital	`ProceedsFromPaymentsToMinorityShareholders`	$27.30K	USD	Annual
Borrowings on lines of credit related party	`ProceedsFromRelatedPartyDebt`	$5.00M	USD	Annual
Borrowings on lines of credit related party	`ProceedsFromRelatedPartyDebt`	$8.00M	USD	Annual
Advances by NMM to ApolloMed prior to the Merger	`ProceedsFromPaymentsForOtherFinancingActivities`	$-9.00M	USD	Annual
Advances by NMM to ApolloMed prior to the Merger	`ProceedsFromPaymentsForOtherFinancingActivities`	-	USD	Annual
Repayments on bank loan	`RepaymentsOfRelatedPartyDebt`	$495.13K	USD	Annual
Repayments on bank loan	`RepaymentsOfRelatedPartyDebt`	-	USD	Annual
Payment of capital lease obligations	`RepaymentsOfDebtAndCapitalLeaseObligations`	$102.35K	USD	Annual
Payment of capital lease obligations	`RepaymentsOfDebtAndCapitalLeaseObligations`	$98.73K	USD	Annual
Proceeds from exercise of stock options included in liabilities	`ProceedsFromStockOptionsExercisedIncludedInLiabilities`	-	USD	Annual
Proceeds from exercise of stock options included in liabilities	`ProceedsFromStockOptionsExercisedIncludedInLiabilities`	$425.02K	USD	Annual
Proceeds from exercise of stock options and warrants	`ProceedsFromWarrantExercises`	$164.80K	USD	Annual
Proceeds from exercise of stock options and warrants	`ProceedsFromWarrantExercises`	$4.00M	USD	Annual
Proceeds from common stock offering	`ProceedsFromIssuanceOfCommonStock`	$2.16M	USD	Annual
Proceeds from common stock offering	`ProceedsFromIssuanceOfCommonStock`	$200.00K	USD	Annual
Repurchase of common shares	`PaymentsForRepurchaseOfCommonStock`	$5.05M	USD	Annual
Repurchase of common shares	`PaymentsForRepurchaseOfCommonStock`	$3.18M	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-11.18M	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-14.98M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-10.86M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$63.57M	USD	Annual
Cash, cash equivalents and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$107.64M	USD	Point-in-time
Cash, cash equivalents and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$118.50M	USD	Point-in-time
Cash, cash equivalents and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$54.93M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$107.64M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$118.50M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$54.93M	USD	Point-in-time
Cash paid for income taxes	`IncomeTaxesPaid`	$24.36M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaid`	$23.64M	USD	Annual
Cash paid for interest	`InterestPaidNet`	$51.04K	USD	Annual
Cash paid for interest	`InterestPaidNet`	$462.34K	USD	Annual
Cashless exercise of stock options	`CashlessExerciseOfStockOptions`	$-109.00	USD	Annual
Cashless exercise of stock options	`CashlessExerciseOfStockOptions`	-	USD	Annual
Deferred tax liability adjusted to goodwill	`DeferredTaxLiabilityAdjustedToGoodwill`	-	USD	Annual
Deferred tax liability adjusted to goodwill	`DeferredTaxLiabilityAdjustedToGoodwill`	$1.11M	USD	Annual
Purchase price adjustment for acceleration of vested stock options	`PurchasePriceAdjustmentForAccelerationOfVestedStockOptions`	-	USD	Annual
Purchase price adjustment for acceleration of vested stock options	`PurchasePriceAdjustmentForAccelerationOfVestedStockOptions`	$868.00K	USD	Annual
Conversion of loan receivable to investment in Accountable Health Care, IPA	`NonCashOrPartNonCashAcquisitionConversionOfLoanReceivableToInvestmentInterest`	-	USD	Annual
Conversion of loan receivable to investment in Accountable Health Care, IPA	`NonCashOrPartNonCashAcquisitionConversionOfLoanReceivableToInvestmentInterest`	$5.00M	USD	Annual
Reclassification of dividends related to share repurchase	`ReclassificationOfDividendsRelatedToSharesRepurchase`	$4.22M	USD	Annual
Reclassification of dividends related to share repurchase	`ReclassificationOfDividendsRelatedToSharesRepurchase`	-	USD	Annual
Reclassification of APS noncontrolling interest to equity related to purchase of additional shares	`ReclassificationOfAPSNonControllingInterestToEquity`	$2.83M	USD	Annual
Reclassification of APS noncontrolling interest to equity related to purchase of additional shares	`ReclassificationOfAPSNonControllingInterestToEquity`	-	USD	Annual
Distribution of warrants to former NMM shareholders	`AdjustmentOfWarrantsGrantedForServices`	-	USD	Annual
Distribution of warrants to former NMM shareholders	`AdjustmentOfWarrantsGrantedForServices`	$5.29M	USD	Annual
Issuance of common stock upon conversion of debt and accrued interest	`ConversionOfStockAmountIssued1`	$5.38M	USD	Annual
Issuance of common stock upon conversion of debt and accrued interest	`ConversionOfStockAmountIssued1`	-	USD	Annual
Reclassification of liability for unissued common shares payable to equity	`ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity`	-	USD	Annual
Reclassification of liability for unissued common shares payable to equity	`ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity`	$1.24M	USD	Annual
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$106.89M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$99.75M	USD	Point-in-time
Restricted cash long-term - letters of credit	`RestrictedCashNoncurrent`	$745.47K	USD	Point-in-time
Restricted cash long-term - letters of credit	`RestrictedCashNoncurrent`	$745.24K	USD	Point-in-time
Restricted cash short-term - distributions to former NMM shareholders	`RestrictedCashCurrent`	-	USD	Point-in-time
Restricted cash short-term - distributions to former NMM shareholders	`RestrictedCashCurrent`	$18.01M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$107.64M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$118.50M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$54.93M	USD	Point-in-time

Stockholders Equity 30 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$164.18M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$181.54M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$87.59M	USD	Point-in-time
ASC 606 Adoption	`AdjustmentsToAdoptionOfNewAccountingStandard`	$1.00M	USD	Annual
Net income	`ProfitLoss`	$60.27M	USD	Annual
Net income	`ProfitLoss`	$45.82M	USD	Annual
Purchase price adjustment from Merger	`AdjustmentsToAdditionalPaidInCapitalBusinessCombinationPurchaseConsideration`	$-868.00K	USD	Annual
Purchase of treasury shares	`TreasuryStockValueAcquiredParValueMethod`	$432.11K	USD	Annual
Shares issued for exercise of options and warrants	`StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants`	$4.00M	USD	Annual
Shares repurchased	`StockRepurchasedDuringPeriodValue`	$1.65M	USD	Annual
Shares repurchased	`StockRepurchasedDuringPeriodValue`	$4.20M	USD	Annual
Shares issued for exercise of options and warrants	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.06M	USD	Annual
Shares issued for exercise of options and warrants (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	488,464.00	shares	Annual
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$1.93M	USD	Annual
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$631.56K	USD	Annual
Distribution of derivative assets - warrants	`AdjustmentOfWarrantsGrantedForServices`	-	USD	Annual
Distribution of derivative assets - warrants	`AdjustmentOfWarrantsGrantedForServices`	$5.29M	USD	Annual
Noncontrolling interest capital change	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$859.43K	USD	Annual
Noncontrolling interest capital change	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$27.50K	USD	Annual
Dividends	`Dividends`	$1.98M	USD	Annual
Dividends	`Dividends`	$19.70M	USD	Annual
Reclassification of liability for unissued shares to equity	`StockIssuedDuringPeriodValueConversionOfLiabilityToEquity`	$1.24M	USD	Annual
Effect of share exchange in Merger	`StockIssuedDuringPeriodValueMerger`	$64.42M	USD	Annual
Effect of share exchange in Merger (in shares)	`StockIssuedDuringPeriodSharesMerger`	480,212.00	shares	Annual
Shares issued upon conversion of Alliance Note	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$5.38M	USD	Annual
Acquisition of additional shares in consolidated entity	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$200.00	USD	Annual
Release of 50% holdback shares	`StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares`	-	USD	Annual
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$164.18M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$181.54M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$87.59M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.